Annovis Bio Secures U.S. Patent for TBI Treatment with Buntanetap
Annovis Bio (ANVS) secures U.S. patent for treating traumatic brain injury (TBI) with buntanetap, a potential breakthrough in TBI treatment and neurodegenerative diseases.
This news matters as it represents a significant development in the treatment of traumatic brain injury, a major cause of death and disability in the US. The patent for buntanetap's use in TBI treatment opens up new possibilities for addressing neurodegenerative diseases and mental illnesses, potentially impacting the lives of millions of people.
